BUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被美国食品及药物管理局授予 "突破性疗法 "称号，公司业绩随之飙升

路透中文

Oct 06, 2025

BUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被<a href="https://laohu8.com/S/USFD">美国食品</a>及药物管理局授予 "突破性疗法 "称号，公司业绩随之飙升

10月6日 - ** 斯普鲁斯生物科学公司SPRB.O股价盘前上涨69%至14.89美元

** 该公司称美国食品及药物管理局为其治疗桑菲利波综合症B型的实验性药物特拉糖苷酶α颁发了 "突破性疗法 (link)"标签。

** 该病是一种遗传性疾病，会导致儿童出现进行性脑损伤

** 突破性疗法 (link) 标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物

** 公司计划于 2026 年第一季度向美国提交批准申请

** 截至上一交易日收盘，股价累计下跌 72

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573672671"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573672671\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573672671?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-06 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573672671","market":"us","top_or_hot":-1,"title":"BUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被美国食品及药物管理局授予 \"突破性疗法 \"称号，公司业绩随之飙升","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被<a href=\"https://laohu8.com/S/USFD\">美国食品</a>及药物管理局授予 \"突破性疗法 \"称号，公司业绩随之飙升</title></head><body><p><span>10月6日</span><span> - </span>** 斯普鲁斯生物科学公司<span>SPRB.O</span>股价盘前上涨69%至14.89美元</p><p>** 该公司称美国食品及药物管理局为其治疗桑菲利波综合症B型的实验性药物特拉糖苷酶α颁发了 \"突破性疗法 (link)\"标签。</p><p>** 该病是一种遗传性疾病，会导致儿童出现进行性脑损伤</p><p>** 突破性疗法 (link) 标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物</p><p>** 公司计划于 2026 年第一季度向美国提交批准申请</p><p>** 截至上一交易日收盘，股价累计下跌 72</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被美国食品及药物管理局授予 \"突破性疗法 \"称号，公司业绩随之飙升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被美国食品及药物管理局授予 \"突破性疗法 \"称号，公司业绩随之飙升\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-10-06 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被<a href=\"https://laohu8.com/S/USFD\">美国食品</a>及药物管理局授予 \"突破性疗法 \"称号，公司业绩随之飙升</title></head><body><p><span>10月6日</span><span> - </span>** 斯普鲁斯生物科学公司<span>SPRB.O</span>股价盘前上涨69%至14.89美元</p><p>** 该公司称美国食品及药物管理局为其治疗桑菲利波综合症B型的实验性药物特拉糖苷酶α颁发了 \"突破性疗法 (link)\"标签。</p><p>** 该病是一种遗传性疾病，会导致儿童出现进行性脑损伤</p><p>** 突破性疗法 (link) 标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物</p><p>** 公司计划于 2026 年第一季度向美国提交批准申请</p><p>** 截至上一交易日收盘，股价累计下跌 72</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nL3T3VN0N9:1","article_id":"2573672671","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573672671","pubTimestamp":1759753190,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被美国食品及药物管理局授予 \"突破性疗法 \"称号，公司业绩随之飙升10月6日 - ** 斯普鲁斯生物科学公司SPRB.O股价盘前上涨69%至14.89美元** 该公司称美国食品及药物管理局为其治疗桑菲利波综合症B型的实验性药物特拉糖苷酶α颁发了 \"突破性疗法 \"标签。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","SPRB":"Spruce Biosciences, Inc."},"translate_title":"BUZZ-Spruce Biosciences' results soared as its genetic disease drug was awarded a \"breakthrough therapy\" designation by the U.S. Food and Drug Administration","themeId":"98aa5a071838dbc09973453e152cc1ef","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRB":0.9},"content_text":"BUZZ-斯普鲁斯生物科学公司的遗传性疾病药物被美国食品及药物管理局授予 \"突破性疗法 \"称号，公司业绩随之飙升10月6日 - ** 斯普鲁斯生物科学公司SPRB.O股价盘前上涨69%至14.89美元** 该公司称美国食品及药物管理局为其治疗桑菲利波综合症B型的实验性药物特拉糖苷酶α颁发了 \"突破性疗法 (link)\"标签。** 该病是一种遗传性疾病，会导致儿童出现进行性脑损伤** 突破性疗法 (link) 标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物** 公司计划于 2026 年第一季度向美国提交批准申请** 截至上一交易日收盘，股价累计下跌 72(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}